Glioblastoma multiforme (GBM) is the most frequent and aggressive primary brain tumors in adults. Uncontrolled proliferation and abnormal cell migration are two prominent spatially and temporally disassociated characteristics of GBMs. In this study, we investigated the role of the receptor tyrosine kinase EphB2 in controlling the proliferation/migration dichotomy of GBM. We studied EphB2 gain of function and loss of function in glioblastoma-derived stem-like neurospheres, whose in vivo growth pattern closely replicates human GBM. EphB2 expression stimulated GBM neurosphere cell migration and invasion, and inhibited neurosphere cell proliferation in vitro. In parallel, EphB2 silencing increased tumor cell proliferation and decreased tumor cell migration. EphB2 was found to increase tumor cell invasion in vivo using an internally controlled dual-fluorescent xenograft model. Xenografts derived from EphB2-overexpressing GBM neurospheres also showed decreased cellular proliferation. The non-receptor tyrosine kinase focal adhesion kinase (FAK) was found to be co-associated with and highly activated by EphB2 expression, and FAK activation facilitated focal adhesion formation, cytoskeleton structure change and cell migration in EphB2-expressing GBM neurosphere cells. Taken together, our findings indicate that EphB2 has pro-invasive and anti-proliferative actions in GBM stem-like neurospheres mediated, in part, by interactions between EphB2 receptors and FAK. These novel findings suggest that tumor cell invasion can be therapeutically targeted by inhibiting EphB2 signaling, and that optimal antitumor responses to EphB2 targeting may require concurrent use of anti-proliferative agents.
INTRODUCTION
Gliomas are the most common primary tumors of the central nervous system. Glioblastoma multiforme (GBM), the most predominant and most malignant form of glioma, comprises B10 000 new cases annually in the United States. Despite considerable progress made in modern antitumor therapy, the 2-year survival rate for patients diagnosed with GBM is still only B28%.
1 A major challenge when treating GBM is the propensity for tumor cells to invade adjacent brain tissues, which inevitably leads to tumor recurrence. Histopathological analysis of clinical GBMs reveals that uncontrolled proliferation and tumor cell invasion, two characteristics of GBMs, are spatially and temporarily disassociated behaviors, with tumor cores, containing a highly proliferative population and cells within the more invasive periphery, showing low proliferation rates. 2, 3 The molecular determinants of GBM invasion are only now beginning to be understood, holding promise for development of new therapeutic approaches. Recent clinical observations in patients and studies of preclinical models suggest that a more invasive tumor phenotype emerges in response to vascular endothelial growth factor pathway inhibitors. 4 This highlights the increasing need to understand mechanisms of tumor cell invasion and develop effective anti-invasion therapies. The paucity of intracranial human GBM models that recapitulate the extensively invasive features of GBMs has been a major obstacle for studying tumor invasion and developing anti-invasive therapeutics. 5 New model systems derived from glioblastoma stem-like cells, established as neurospheres under serum-free conditions, recapitulate the genetic and histopathological features of clinical GBMs and provide excellent models for tumor invasion studies. 6 Incorporating these invasive tumor models into drug development regimens should enhance current efforts toward developing effective anti-invasion therapy for glioblastoma.
We recently found that the receptor tyrosine kinase EphB2 is significantly upregulated during differentiation of GBM-derived stem-like neurospheres. 7 Eph receptors and their transmembranebound ligand ephrins form the largest subfamily of the receptor tyrosine kinase. There are nine members of EphA and five members of EphB receptors in mammals that specifically bind to their cognate ligands (ephrin-As and ephrin-Bs, respectively), with few exceptions. 8, 9 Eph receptors and ephrins lead to bi-directional signaling, from ligand to receptor (forward) and from receptor to ligand (reverse), to transduce signals in a cell --cell contact-dependent manner, thereby coordinating cell repulsion or attraction. 8, 9 Eph and ephrin interactions are implicated in diverse developmental and neurological functions, including cell attachment, migration, axon guidance, vasculogenesis and cell motility. 10 The effects of the Eph/ephrin system in cancer are complex and sometimes controversial owing to their diverse nature. 9, 11 Accumulating in vitro studies demonstrate that Eph receptors and ephrins can both promote and inhibit tumorigenicity. Little is known about how the Eph/ephrin system balances these contrasting activities. It has been reported that Eph signaling can elicit a tumor-suppressing effect by inhibiting cancer cell --substrate adhesion, migration, invasion and growth. 12 --15 Ligandinduced forward Eph signaling is associated with inhibition of oncogenic signaling pathways, such as HRAS-Erk, phosphatidylinositol-3-OH kinase (PI3K)-AKT and Abl-Crk, in colon, breast and prostate cancers. 15 --17 Conversely, Eph receptors have been found to promote migration, invasion, metastasis and angiogenesis in certain tumor models, including glioma, breast cancer and hepatocellular carcinomas. 18 --21 Eph receptor can also crosstalk with other receptor tyrosine kinases such as fibroblast growth factor receptor-1, epidermal growth factor receptor and the hepatocyte growth factor receptor c-Met, and thereby increase cancer cell malignancy. 22 --24 A considerable limitation in our understanding of Eph/ephrin function is that the majority of conclusions are based on in vitro studies, rendering their relevance to in vivo contexts uncertain.
EphB2 is expressed in cells of epithelial origin, 21, 25 has strong affinity for ephrin-B1 and ephrin-B2, and weak affinity for ephrin-B3 and ephrin-A5. Like other members of the Eph family, EphB2 elicits both tumor-promoting and tumor-suppressing effects. EphB2 mutant or EphB2 silencing has been identified in human prostate and colorectal tumors, suggesting a tumor-suppressing function for EphB2 forward signaling in these cancers. 26, 27 Yet, in colorectal cancers, EphB2/ephrin signaling is able to inhibit tumor expansion and invasion through repulsive mechanisms. 12, 28 These disparate context-dependent EphB2 functions make it of great interest to study its role in GBM-derived stem-like neurospheres, whose orthotopic xenografts recapitulate with high fidelity the histopathological and invasive phenotypes of clinical GBM. Using a comprehensive array of in vitro and in vivo methods, including internally controlled dual-fluorescence GBM xenografts, we found that EphB2 promotes cell invasion and inhibits proliferation in GBM, essentially recapitulating the balance between the migration/proliferation dichotomy observed in human tumors. We further determined that interactions between EphB2 receptor and the non-receptor tyrosine kinase focal adhesion kinase (FAK) mediate EphB2 function in GBM neurospheres.
RESULTS

EphB2 gain of function promotes GBM neurosphere cell migration and invasion
The human GBM stem-like neurosphere cell lines, HSR-GBM1A and HSR-GBM1B, have been extensively characterized by us and others. 7,29 --32 Both lines generate infiltrative xenografts that recapitulate the histopathological features of clinical GBM when injected intracranially into mouse cortical regions. We examined the expression of EphB2 in HSR-GBM1A and HSR-GBM1B. Immunoblot analysis reveals that, in contrast to non-neoplastic human neural progenitors, EphB2 is upregulated in HSR-GBM1A and HSR-GBM1B lines (Figure 1a ). Reverse transcriptase PCR shows that EphB2 ligands, ephrin-B1, B2 and B3, but not ephrin-A5, are expressed by HSR-GBM1A and HSR-GBM1B cells (Figure 1b) .
High-EphB2-expressing cells were generated by transfecting HSR-GBM1A neurosphere cells with the lentiviral vector pLoc containing human EphB2 cDNA. The cells (designated as EphB2-OVE) were labeled with green fluorescent protein (GFP). Control cells (designated as Ploc) were labeled with Ploc containing red fluorescent protein cDNA (RFP). Western blot analysis established a B2-fold increase of EphB2 expression in EphB2-OVE cells compared with control Ploc cells (Figure 1c ). Fluorescence microscopy confirmed that EphB2-OVE cells were GFP þ and Ploc cells were RFP þ (Figure 1d ). To determine that EphB2 receptors were functional, Ploc and EphB2-OVE cells were stimulated with ephrin-B1/Fc fusion proteins that serve as forward signalingactivating EphB2 ligands. 33, 34 EphB2 receptor phosphorylation was detected by immunoprecipitation using an anti-EphB2 antibody and western blot analysis using an anti-phospho-tyrosine antibody. The ligand ephrin-B1/Fc induced EphB2 receptor activation in EphB2-OVE cells (Figure 1e ). After ligand treatment, the total level of EphB2 in GBM neurospheres decreased (Figure 1e ), consistent with a previously described mechanism of stimulationinduced Eph receptor degradation. 33, 35 We asked if EphB2 upregulation alters the migratory phenotype of GBM neurosphere cells. Ploc and EphB2-OVE cell migration was analyzed on laminin-coated transwells 36 and quantified by counting 4 0 -6-diamidino-2-phenylindole (DAPI)-stained cells per field (Figure 2a) . Overexpression of EphB2 alone, in the absence of exogenous ligand stimulation, promoted a 2-to 3-fold increase in serum-induced cell migration when measured 4 --18 h after plating cells (Figure 2b , Po0.001). We also tested neurosphere cell migration induced by hepatocyte growth factor, a potent chemoattractant for neural progenitor cells, 37 in serum-free neurosphere culture medium. EphB2 similarly promoted GBM neurosphere cell migration in response to this stimulus (Figure 2c , Po0.001). In addition, we found that EphB2 promoted neurosphere cell invasion through matrigel-coated transwells (Supplementary Figure 1A , Po0.001). We used EphB2/Fc as a competitive antagonist of EphB2 receptors to determine the role of EphB2 on this migration response. 38, 39 EphB2/Fc inhibited cell migration in both Ploc and EphB2-OVE cells by B50% (Figure 2d , Po0.001), suggesting that both endogenous and transgenic EphB2 receptor activities are involved in promoting cell migration. When the EphB2 ligand ephrin-B1/Fc was added in combination with serum, cell migration was further increased compared with cells stimulated with serum alone (Figure 2e , Po0.001). EphB2 overexpression similarly enhanced cell migration in a two-dimensional scratch assay (Figure 2f ). We measured the width of cell-free clearing produced by the scratch at days 0, 1 and 4, and Our results show that EphB2 is both pro-migratory and antiproliferative in GBM stem-like neurospheres. To determine the general relevancy of these findings, we examined EphB2 gain of function in the neurosphere cell line GBM-DM14602 and in primary GBM neurospheres derived from the Mayo 22 xenograft line. 40 EphB2 overexpression (Supplementary Figure 1C ) inhibited in vitro cell growth (Figures 3e and g ) and stimulated cell migration (Figures 3f and h ) in these additional neurosphere models.
EphB2 loss of function inhibits proliferation and promotes migration The results presented above support pro-migratory/invasive and anti-proliferative actions of EphB2 in GBM-derived neurosphere cells. To corroborate these findings, we evaluated the effects of knocking down endogenous EphB2 expression in GBM neurospheres. Western blot analysis showed that, compared with controls (designated as NS for non-silenced), two EphB2 short-hairpin RNAs (shRNAs) achieved B90% inhibition of EphB2 expression in HSR-GBM1A neurosphere cells (designated as EphB2KD1 and EphB2KD2; Figure 4a ). In order to visually detect cells transfected with the shRNA, NS and EphB2KD cells were labeled with GFP ( Supplementary Figures 2A --D) . We found that EphB2 knockdown significantly inhibited serum-induced neurosphere cell migration by 40 --55% (Figures 4b and c, Po0 .001), consistent with the decreased GBM neurosphere cell migration observed in response to the EphB2 competitive antagonist EphB2/Fc (Figure 2d ). EphB2 knockdown also promoted neurosphere cell growth as evidenced by increased cell number and neurosphere formation (Figures 4d and e) . The pro-proliferative effect of EphB2 knockdown was further confirmed by cell-cycle analysis, showing that EphB2 knockdown increased cells at S phase by 31% (Figure 4f , Po0.01). EphB2KD1 cells showed a 33% increase in 5-ethynyl-2 0 -deoxyuridine (EdU) incorporation compared with control cells (Figure 4g and Supplementary Figure 2E , Po0.05). In addition, cyclin B levels increased B2.2-fold in EphB2KD1 cells (Figure 4h , Po0.05), consistent with the decreased cyclin B expression in response to EphB2 gain of function as shown in Figure 3d . These results support an inhibiting effect of endogenous EphB2 receptors on cell proliferation.
We further examined the effect of EphB2 on the stem cell properties of GBM neurospheres. We found that EphB2 overexpression or knockdown did not change the 'stemness' of GBM neurospheres, as indicated by stem cell marker expression in control and experimental cells using real-time PCR (Supplementary Figures 3A and B) . In addition, we examined the expression of the stem cell surface marker CD133 and the differentiation marker glial fibrillary acidic protein in Ploc, EphB2-OVE, NS and EphB2KD1 cells by immunoblot analysis. EphB2 overexpression or knockdown did not change the expression of these markers (Supplementary Figure 3C) . Thus, at the molecular level, changes in EphB2 expression did not appear to alter the GBM stem cell phenotype.
Xenografts from EphB2-overexpressing GBM neurospheres recapitulate the proliferation/migration dichotomy We used an internally controlled dual fluorescence model system to determine the effect of EphB2 on tumor invasion in vivo. A 1:1 mixture of RFP þ Ploc cells and GFP þ EphB2-OVE cells (5000 each) was implanted into the mouse striatum and mice were killed 67 days after transplant for histological analysis. EphB2-OVE cells clearly showed an enhanced invasive phenotype as shown in . Thus, our data show that EphB2 promotes a more invasive phenotype with less proliferation in GBM neurospheres, effectively recapitulating the balance between invasion and proliferation observed in human neoplasms. By contrast, we used the same dual fluorescence approach and generated intracranial xenografts from EphB2-overexpressing U87 cells and control cells. EphB2 did not promote invasion in the relatively noninvasive U87 models (Supplementary Figures 4A --C) .
FAK mediates EphB2 function in GBM neurosphere cells As serum differentially induced migration and invasion in these cells, we compared the signaling pathways activated by serum in Ploc and EphB2-OVE cells. No significant differences were observed in AKT and mitogen-activated protein kinase (MAPK) activation in response to serum (Figure 6a ). However, immunoblot analysis of total cell protein using the anti-phospho-(Ser/Thr)-AktSub antibody, which recognizes consensus AKT substrate sites in multiple proteins [RxRxx(S/T)(F/L)], demonstrated stronger phosphorylation of AKT substrates in EphB2-OVE cultures. Furthermore, serum-induced FAK phosphorylation (Y576/577) increased substantially in EphB2-OVE cells (3.1-fold), but only slightly in Ploc cells (Figure 6a ). This suggests that AKT downstream targets and the FAK signaling pathway mediate EphB2-induced cell migration. PI3K-AKT activity has been previously linked to cell migration induced by Eph receptors. 41 Studies by Genander et al. 38 showed that EphB2 uses PI3K to inhibit migration in intestinal cells. We asked what role does FAK have in EphB2-mediated migration. Treating Ploc and EphB2-OVE cells with the agonist ephrin-B1/Fc for 15 min did not activate AKT and MAPK but increased FAK phosphorylation (Y576/577) three-fold in EphB2-OVE cells (Figure 6b , Po0.05). In addition, we found that EphB2 co-immunoprecipitated with FAK in EphB2-OVE cells (Figure 6c ), indicating that EphB2 complexes either directly or indirectly with FAK. As FAK activation has an important role in cell adhesion and migration, we studied focal adhesion and cytoskeleton structure in Ploc and EphB2-OVE cells. We examined the influence of EphB2 on the focal adhesion formation of cells grown on laminin-coated surfaces using an anti-vinculin antibody. Striking differences in focal adhesion formation were observed between Ploc and EphB2-OVE cells (Figure 6d ). Compared with Ploc cells, strong, punctate vinculin staining in filopodial-like cytoplasmic projections were observed in EphB2-OVE cells, suggesting an increased amount of focal adhesions were formed (Figure 6d , arrows in the higher magnification photomicrograph indicate focal adhesions). Ploc and EphB2-OVE cells were further stained with a FAK antibody and phalloidin, which detects polymerized actin (F-actin) in cells. FAK and F-actin colocalized in EphB2-OVE cells much more frequently in comparison with Ploc cells (Figure 6e , arrows indicate colocalization). These findings show that FAK activation mediates EphB2-induced cell adhesion, Figure 2 . Functional EphB2 receptor promotes neurosphere cell migration and invasion. (a, b) EphB2 overexpression promoted GBM neurosphere cell migration on laminin-coated transwells. An equal number of Ploc or EphB2-OVE cells were plated on laminin-coated transwells. Serum was added to the bottom well of the transwells. Cells migrated toward serum were stained with DAPI (f; bar ¼ 50 mm) and counted in five fields per transwell at different time points, and plotted as in panel g. EphB2-OVE cells migrated 2-to 3-fold faster than control cells after plating for 4 --18 h (***Po0.001, n ¼ 6). (c) EphB2 overexpression promoted GBM neurosphere cell migration in response to hepatocyte growth factor. Hepatocyte growth factor (100 ng/ml) was added to the bottom chambers of the transwells in serum-free neurosphere medium and cells migrated were counted after 18 h of incubation (***Po0.001, n ¼ 6). (d) Human EphB2/Fc, as an antagonist, significantly inhibited serum-induced cell migration in Ploc and EphB2-OVE cells (18 h after plating; ***Po0.001, n ¼ 6). (e) When Ploc and EphB2-OVE cells were treated with the ligand ephrin-B1 (1 mg/ml), there was a further increase in cell migration (18 h) in EphB2-OVE cells (***Po0.001, *Po0.05; n ¼ 6). (f) Scratch assay indicated that EphB2 overexpression promoted cell motility. Bar ¼ 5 mm. (g) Compared with Ploc cells, EphB2-OVE cells moved 7.6-fold longer after wound for 4 days (***Po0.001, n ¼ 10).
actin cytoskeleton organization and ultimately cell migration. We asked if inhibiting FAK pathways would affect serum-induced cell migration in EphB2-OVE cells using two specific pharmacological FAK inhibitors PF573228 (100 nmol/l) 42 and FAK inhibitor 14 (10 mmol/l).
43 EphB2-OVE cell migration was almost completely blocked by PF573228 (490%, Po0.001) and FAK inhibitor 14 (490%, Po0.001) in transwell assay (Figure 6f ). Western blot analysis indicated that PF573228 completely inhibited seruminduced FAK phosphorylation in EphB2-OVE cells under these experimental conditions (Supplementary Figure 6) . On the other hand, PF573228 and FAK inhibitor 14 blocked Ploc cell migration by 45% and 50%, respectively (Figure 6g ). We also found that two specific PI3K pharmacological inhibitors, LY294002 (10 mmol/l) and wortmannin (10 mmol/l), 44 block cell migration in both Ploc and EphB2-OVE cells to a similar extent (Figures 6f and g ). By contrast, the MAPK inhibitor PD98059 had no effect on cell migration (Figure 6f ). Collectively, these results suggest that both PI3K-AKT and FAK are required for migration of GBM stem-like neurospheres, and that FAK activation has a dominant role in EphB2-induced cell migration. 
DISCUSSION
In this work, we show that the receptor tyrosine kinase EphB2 promotes cells invasion using GBM models that recapitulate clinical tumor histopathy with high fidelity. Simultaneously, we found that EphB2 inhibits cell proliferation in these models, implicating that EphB2 regulates the proliferation/migration dichotomy of clinical GBMs. Furthermore, the interactions between EphB2 receptor and FAK have a role in the pro-migratory function of EphB2 in GBM neurospheres.
The effect of EphB2 on GBM cell migration has been studied previously in vitro and ex vivo using adherent GBM cell lines established and passaged extensively in serum-containing medium. 33, 45 However, the extent to which findings using relatively non-invasive models predict EphB2 effects in highly invasive human tumors remains a question. In fact, we did not observed the same pro-migratory effect of EphB2 in xenografts derived from the adherent U87 cell line. Our present study used GBM-derived neurospheres established and maintained under (10 000) or EphB2-OVE cells (10 000) were separately implanted into mouse brain. Animals were killed 67 days after implantation and brain sections were subjected for immunohistochemistry. Ki-67 staining showed that xenografts from Ploc cells had more cells under proliferation than that from EphB2-OVE cells. (j) Quantification of Ki-67 þ cells in xenografts by taking pictures and counting positively stained cells. Xenografts from Ploc cells had 70% higher Ki-67 þ staining than that from EphB2-OVE cells (***Po0.001, n ¼ 10).
non-adherent serum-free medium, conditions that maintain genomic integrity and enrich for tumor-initiating stem-like cells. 6, 46 Furthermore, GBM neurosphere-derived xenografts recapitulate the pathological features of clinical glioblastoma, including extensive invasiveness. Our internally controlled dualfluorescent approach clearly showed that EphB2 gain of function induces a more prominently invasive phenotype, consistent with published data showing that the EphB2/ephrin-B tyrosine kinase system is associated with invasive phenotype in clinical GBM samples. 33, 47, 48 Interestingly, the NCI Rembrandt database does not reveal a correlation between EphB2 expression levels and highgrade gliomas. This is likely due to the fact that both low-and highgrade lesions are characteristically invasive, and perhaps the bias in which the database predominantly represents tumor cores without comparisons between more invasive tumor periphery cells. 49 The pro-invasive and anti-proliferative actions of EphB2 in GBMderived neurospheres represent another example of the diverse functions of Eph receptors in tumor biology. The effect of EphB2 on GBM neurosphere cell growth is consistent with the findings of Nakada et al. 45 showing that EphB2 reduces cell growth in U87 GBM cells. In GBM neurosphere cells, we detected cell number, cell cycle and cyclin expression in response to EphB2 overexpression or knockdown. Most of our EphB2 gain-of-function and loss-offunction data agreed with each other, indicating an antiproliferative role of EphB2. In our cell-cycle assay, we detected small changes in S phase, likely because we performed the cellcycle assays in unsynchronized cell populations. We believe these small changes reflect the differences we observed in cell growth, as we reported elsewhere. 50 In the cyclin analysis, cyclin D1 was decreased by EphB2 overexpression, but not increased in EphB2-knockdown cells. One potential explanation for this inconsistency is that variations may exist among the different stable lines we used for these studies.
The fact that EphB2 has both pro-migratory and antiproliferative effects in vivo may reflect the migration/proliferation dichotomy in GBMs. 3 Although this 'go-or-grow' phenomenon of GBM has been documented for over a decade, 2,3 its underlying cellular and molecular mechanisms are largely unknown. Our findings that EphB2 gain of function has both pro-migratory and anti-proliferative effects in the same cells provide one mechanism for the 'go-or-grow' behavior in GBM. GBM neurosphere cultures contain both stem-like cells, transient amplifying progenies and more differentiated progenitor cells. We noticed that even though EphB2 reduced proliferation and neurosphere formation in GBM neurosphere cultures, overexpressing or knocking down EphB2 did not alter the stem cell pool as evidenced by stem cell marker expression in the neurosphere cultures. It is likely that EphB2 affects the growth of both stem-like cells and progenitor cells to the same extent.
In our migration assay, we mainly used 10% serum as the chemoattractant as serum is commonly used in glioma cell migration assays, and contains multiple factors that could be present in the brain microenvironment and function as chemotactic sources for tumor cell migration in vivo. As we obtained similar results in response to hepatocyte growth factor in serumfree medium, we essentially ruled out any potential role for seruminduced cell differentiation in the observed migration responses.
EphA2, another member of the Eph-receptor family, has been extensively studied in cancer biology. 23, 35, 41, 51 EphA2 overexpression elicits pro-migratory effects in GBM through ligand-independent mechanisms, whereas ligand-dependent activation of EphA2 prevents GBM cell migration. The pro-migratory effect of EphB2 overexpression in GBM neurosphere cells is likely to be liganddependent, as EphB2/Fc, which acts as a decoy receptor and sequesters ligands, blocked cell migration in EphB2-OVE cells. The fact that EphB2/Fc also blocked control Ploc cell migration indicates that the endogenous EphB2 activities also contribute to the pro-migratory function of EphB2. As EphB2 ligands are expressed by GBM neurospheres, cell contact-mediated activation of EphB2 could contribute to the baseline EphB2 phosphorylation. However, there is a possibility that EphB2/Fc may stimulate ephrin-B reverse signaling in our models. Future studies with various EphB2 constructs are needed to definitively distinguish the involvement of EphB2 kinase activity in GBM migration. Furthermore, in EphA2-induced cell migration, the PI3K-AKT pathway appears to have a major role in cell migration. In our models, we found that both FAK and PI3K-AKT pathways are involved in GBM neurosphere cell migration. Our findings that pharmacological PI3K inhibitors prevent both Ploc and EphB2-OVE cell migration to a similar extent suggest that the PI3K-AKT pathway contributes in a general manner to GBM neurosphere migration. This is consistent with our western blot analysis that there is no difference in AKT activation in Ploc and EphB2-OVE cells in response to serum or ephrin-B1/Fc. However, in EphB2-OVE cells there is a stronger phosphorylation of AKT substrates. One potential explanation of these findings is that EphB2 signaling has other effects on downstream PI3K-AKT signaling, such as phosphatase inhibition. Future comprehensive of EphB2-OVE cells, and immunoprecipitated using an anti-FAK antibody followed by detection using anti-EphB2 antibody. In EphB2-OVE cells, EphB2 can be co-immunoprecipitated with FAK. (d) Ploc and EphB2-OVE cells were grown on laminin-coated glass slides for 40 min and stained with an anti-vinculin antibody (1:100) and an Alexa Fluor 647-conjugated secondary antibody. Fluorescence pictures were taken using a fluorescent microscope and the Axiovision program. In EphB2-OVE cultures, strong and punctuated vinculin stainings were found in the spreading edges of the cytoplasma, suggesting formation of focal adhesions (arrows). In Ploc cells, vinculin staining were less spread out, suggesting less focal adhesions were formed. Higher magnification microphotographs are shown in the middle and right panels. (e) Ploc and EphB2-OVE cells were grown on laminin-coated glass slides for 2 h and stained with an anti-FAK antibody (1:200) and Alexa Fluor 647-conjugated phalloidin to detect F-actin. As Ploc cells were RFP þ, FAK was detected using an Alexa Fluorescent 488-conjugated secondary antibody in Ploc cells. And FAK in EphB2-OVE cells (GFP þ ) was detected using a Cy3-conjugated secondary antibody. Fluorescence pictures were taken using a fluorescent microscope and the Axiovision program, and analyzed using ImageJ. For simplicity, we used the same color code for both Ploc and EphB2-OVE cells: green for FAK and red for F-actin. In many EphB2-OVE cells, FAK tends to colocalized with F-actin. EphB2-driven proteomic responses should shed light on novel mechanisms of GBM migration.
FAK pathway inhibitors reduced more than 90% cell migration of EphB2-OVE cells but only 50% in control Ploc cells, suggesting that the FAK signaling pathway is the pivotal mediator of EphB2-induced cell migration. The two FAK inhibitors used are highly specific for FAK, with 50-to 250-fold selectivity over other protein kinases. 42, 43 FAK is a convergence point for growth factors and integrins, and is crucial for a variety of cellular processes, including cell spreading, adhesion, migration, survival, anoikis, proliferation, differentiation, and angiogenesis. 52 --55 FAK has been shown previously to function downstream from EphB2 in the regulation of neuronal synaptic structures. 56 Our findings that EphB2 --FAK interactions mediate the migratory effect in GBM neurosphere cells are consistent with the findings in breast cancer-initiating cells that FAK is not required for tumor initiation but for tumor cell migration. 57 Thus, FAK is an important target for tumor invasive drug design. In fact, several FAK inhibitors have been developed and are currently under clinical trials. Some of them show promising antitumor effects. 58 FAK influences cell migration by activating three major pathways, that is, the Src-Cas-Crk pathway, the PI3K-AKT pathway and RhoA subfamily of small GTPases. 52, 59 We found that PI3K inhibition only partially reduced GBM neurosphere cell migration induced by EphB2, suggesting that other pathways mediate EphB2-induced cell migration. For example, R-Ras has been reported to mediate EphB2-induced cell migration in U87 GBM cells. 45 Our findings have several other clinical implications. Current antitumor strategies such as chemotherapy and radiotherapy mostly target the highly proliferative tumor cell population. Therefore, invasive cells can escape surgical and anti-proliferative therapies through their geometric location and low proliferation rate. EphB2 overexpression may contribute to these resistance mechanisms, since it induces a migratory proliferatively silent phenotype. Currently, Eph receptor-targeting reagents are being developed for cancer therapy. 9, 60 Our novel findings predict that EphB2 pathway inhibitors will be anti-invasive in GBM subsets and that this strategy risks inducing a more highly proliferative phenotype. Thus, successful application of EphB2 inhibitors may require concurrent use of anti-proliferative modalities such as chemotherapy and/or radiation therapy.
MATERIALS AND METHODS
Cell culture and reagents
All reagents were purchased from Sigma Chemical Co. (St Louis, MO, USA) unless otherwise stated. Ephrin-B1/Fc, EphB2/Fc and human Fc were purchased from R&D systems (Minneapolis, MN, USA). The FAK inhibitors PF573228 and FAK inhibitor 14 were purchased from Tocris Bioscience (Ellisville, MO, USA). The human glioblastoma neurosphere lines HSR-GBM1A (0913) and HSR-GBM1B (0627) was originally derived by Dr A Vescovi and co-workers and maintained in serum-free medium supplemented with epidermal growth factor (PeproTech, Rocky Hill, NJ, USA) and fibroblast growth factor (PeproTech). 7, 29, 31, 32, 46 Cells were incubated in a humidified incubator containing 5% CO 2 /95% air at 37 1C and passaged every 4 --5 days. The GBM-DM140207 neurosphere line was derived from a glioblastoma at the University of Freiburg and provided by Dr Jaroslaw Maciaczy. 7 The neurosphere cultures from the primary xenograft line Mayo 22 40 were generated using the same methods and culture conditions as described in Galli et al. 46 Mayo 22 neurosphere cultures were used at passage p10.
Viral transfection
Viral expression vector pLoc containing RFP or EphB2 cDNA plus GFP (cat. no. OHS5898-100998954) was obtained from Open Biosystems (Huntsville, AL, USA). EphB2 and GFP were separately transcribed as there is a stop code between them (http://www.openbiosystems.com/collateral/ genomics/pi/Precision%20LentiORFs/Precision_LentiORF_Technical_Manual. pdf). Virus was packaged using the Viral Power Packaging system (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's forward transfection instructions. Viruses were collected by centrifugation at 3000 r.p.m. for 15 min. Neurosphere cells (HSR-GBM1A, GBM-DM140207, Mayo 22 neurospheres) were transfected with virus containing pLoc/RFP or pLoc/EphB2/GFP for 48 h before antibiotic blasticidin (2 mg/ml) was added. For transfected HSR-GBM1A cells, pooled transfectants were further sorted for RFP þ or GFP þ cells at The Flow Cytometry Facility at Johns Hopkins School of Public Health.
To knock down EphB2 expression in GBM neurospheres, virus containing an EphB2 shRNA in a GIPZ viral expression vector along with a control non-silencing sequence in the same GIPZ vector were obtained from Open Biosystems. Neurosphere cells were transfected with virus for 48 h followed by antibiotic selection with puromycin (4 mg/ml).
Reverse transcriptase PCR and quantitative real-time PCR Total RNA (1 mg) was reverse-transcribed using the oligo(dT)12-18 primer and Superscript II (Invitrogen) according to the manufacturer's instructions. The primers used to amplify ephrins are as follows: Ephrin-B1_sense: ggaggcagacaacactgtca, antisense: gaacaatgccaccttggagt; Ephrin-B2_sense: atccaacaagacgtccagaa, antisense: CTGA; ephrin-B3_sense: gaggcatgaag gtgcttctc, antisense: gaggttgcattgctggt; ephrin-A5-Sense: tctcctctgcaatccc agata, antisense: tacggtgtcatctgctggtt. The thermal cycling conditions were as follows: 95 1C for 5 min, followed by 40 cycles of 95 1C for 10 s, 55 1C for 10 s and ending with 72 1C for 30 s.
Quantitative real-time PCR was performed according to Pfaffl et al. 61 The primers are as follows: CD133_sense: ctggggctgctgtttattattctg, antisense: acgccttgtccttggtagtgttg; nestin_sense: AGGATGTGGAGGTAGTGAGA, antisense: ggagatctcagtggctctt; Musashi-1_sense: gagactgacgcgccccagcc, antisense: cgcctggtccatgaaagtgacg; Sox-2_sense: accggcggcaaccagaagaacag, antisense: gcgccgcggccggtatttat. Total RNA (1 mg) was reverse-transcribed using the oligo(dT)12 --18 primer and Superscript II (Invitrogen) according to the manufacturer's instructions. Quantitative real-time PCR was performed using an Applied Biosystems Prism 7900 HT Sequence Detection System using SYBR Green PCR Master Mix (Applied Biosystems, Forster City, CA, USA). The thermal cycling conditions were as follows: 95 1C for 5 min, followed by 40 cycles of 95 1C for 10 s, 55 1C for 10 s and ending with 72 1C for 30 s. Samples were amplified in triplicate and data were analyzed using the Applied Biosystems Prism Sequencer Detection Software Version 2.3 (Applied Biosystems). Human 18S rRNA was amplified as endogenous control. Relative expression of each gene was normalized to the 18S-rRNA control.
Neurosphere assays
For neurosphere assay, 29, 31 GBM neurospheres were dissociated and seeded at a density of 5 Â 10 3 /cm 2 in six-well plates containing neurosphere culture medium. Cells were incubated for 5 --7 days and neurospheres were transferred into 1% agarose, fixed and stained with Wright solution (1%). Neurosphere number and size were analyzed by computer-assisted morphometry (MCID; Linton, Cambridge, UK). Number of neurospheres X100 mm in diameter in three random microscopic fields per well were measured.
Cell migration and invasion assay
Both sides of a transwell (Corning, Lowell, MA, USA) were coated with 10 mg/ml laminin at 37 1C overnight followed by washing with phosphatebuffered saline (PBS) for three times. 35, 36 GBM neurosphere cells were incubated in growth factor-free medium for 24 h and cells were suspended at 1 Â 10 6 cells/ml. One hundred microliters of cell suspension were added to the upper chamber of the transwell. Minimum Essential Medium Eagle medium (650 ml) containing 10% fetal calf serum was added to the lower chamber. In some studies, ephrin-B1/Fc (1 mg/ml) or human Fc (1 mg/ml) was added to the lower chamber. When inhibitors were used, cells were incubated with inhibitors for half an hour prior to being added to the upper chamber. The cells were then pelleted at 1000 r.p.m. for 10 min and EphB2 in glioblastoma proliferation and migration SD Wang et al resuspended in growth factor-free medium infused with the appropriate inhibitors. After overnight incubation at 37 1C, cells were fixed with the Diff-Quick kit (Fisher Scientific, Pittsburgh, PA, USA). Cells on the upper side of transwells were gently wiped off with Q-tips. Cells migrating through the filter were stained with DAPI (Vector Laboratories, Burlingame, CA, USA). Migration was quantified by counting cells in five selected fields of view per transwell using Â 10 magnification in triplicates in at least three independent experiments. For invasion assay, we performed a similar procedure using growth factor-reduced, matrigel-coated transwells (BD Biosciences, Bedford, MA, USA). Cells invading into the bottom well were quantified after 48 h of incubation.
Scratch assay
GBM neurosphere cells were grown on poly-L-lysine (100 mmol/l)-and 10 mg/ml laminin-coated 35-mm dishes until confluent. Cultures were treated with mitomycin C (1 mg/ml) for half an hour and then washed with PBS three times. Several scratches were performed using a 10-ml pipette tip through the cells. A mark was drawn on the bottom of the dish for identification purposes. Phase-contrast pictures were taken at different time points under a Â 10 object. Distances were measured and quantified as described previously.
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Cell adhesion assay Cell-cycle analysis and EdU staining Cell cycle was analyzed by flow cytometry using a FACSCalibur (Becton Dickinson, Mountain View, CA, USA). 50 Briefly, GBM neurosphere cells were collected and dissociated by vigorously pipetting. Cells were fixed with 75% ethanol at 4 1C for 30 min. Cells were incubated with DNase-free RNase at 37 1C for 30 min followed by propidium iodide (100 ng/ml) for 1 h at 37 1C. The percentage of cells at each cell-cycle phase (G 1 /G 0 , S and G 2 /M) was analyzed by using the CellQuest software (Becton Dickinson).
EdU staining was performed using the Click-iT EdU Imaging Kit (Invitrogen) according to the manufacturer's protocol, with modifications. GBM neurospheres were collected and fixed with 4% paraformaldehyde in PBS for 15 min. After washing twice with PBS containing 3% bovine serum albumin, cells were permeabilized with PBS containing 0.5% Triton X-100 for 20 min. The cells were incubated with a Click-iT reaction cocktail containing Click-iT reaction buffer, CuSO 4 , Alexa Fluor 594 Azide and a reaction buffer additive for 30 min. After washing with PBS, the cells were centrifuged onto glass slides and covered with Vectashield mounting medium containing DAPI (Vector Laboratories). EdU-positive cells were counted and quantified under a fluorescent microscope.
Cell stimulation, immunoprecipitation and immunoblotting
To study the signaling events after serum or ligand stimulation, GBM neurospheres were dissociated to single-cell suspension by mechanical force and starved in growth factor-free medium for 4 h followed by treatment with fetal calf serum (10%) or ephrin-B1/Fc (1 mg/ml) for 15 min. Cells were lysed with radioimmunoprecipitation assay buffer (50 mM Tris --HCl (pH 7.4), 150 mM NaCl, 1% NP-40, 0.25% Na-deoxycholate) containing protease and phosphatase inhibitors (Calbiochem, San Diego, CA, USA), and sonicated for 15 s; the suspensions were centrifuged at 3000 g for 10 min. Protein concentrations were determined using the Coomassie Protein Assay Reagent (Pierce, Rockford, IL, USA). Immunoprecipitation of EphB2 or total FAK was performed as described previously. 15, 33 In brief, 300 mg of total proteins were incubated with goat anti-EphB2 (9 mg; R&D Systems, Minneapolis, MN, USA) or rabbit anti-total FAK (1:200) for 18 h at 4 1C. Corresponding IgG was used as negative control. Protein --antibody complexes were precipitated with protein G --Sepharose beads (50 ml; GE Healthcare, Piscataway, NJ, USA) and the precipitates were eluted by boiling in 2 Â sodium dodecyl sulfatesample buffer (3% sodium dodecyl sulfate, 1% b-mearcaptoethanol, 10% glycerol, 62.5 mM TRIS base, 0.005% Bromophenol blue). Proteins were separated using 4 --20% sodium dodecyl sulfate --PAGE gels (Lonza, Williamsport, PA, USA) and blotted onto nitrocellulose membranes (GE Healthcare). 50 The membranes were incubated in Odyssey Licor blocking buffer (LI-COR Biosciences, Lincoln, NE, USA) for 1 h at room temperature and then overnight with primary antibodies at 4 1C in Odyssey blocking buffer. After rinsing, membranes were incubated with IRDye secondary antibodies (1:15 000 --1:20 000; LI-COR Biosciences) and protein expression changes were quantified by dualwavelength immunofluorescence imaging (Odyssey Infrared Imaging System; LI-COR Biosciences) scanning of the membranes as described previously. 7, 62 To detect phosphorylation of EphB2, an anti-phosphotyrosine mouse monoclonal antibody (Cell Signaling Technology, Danvers, MA, USA) was used and membranes were reprobed with mouse antiEphB2 antibodies (Abcam, Cambridge, MA, USA).
For immunoblotting, all primary antibodies were purchased from Cell Signaling Technology unless otherwise stated: anti-phospho-tyrosine, anti-total-AKT, anti-phospho-AKT, anti-phospho-(Ser/Thr) AKT-substrate, anti-total MAPK (BD Biosciences), anti-phospho-MAPK, anti-total FAK, anti-phospho-Try576/577-FAK and anti-b-actin. Antibodies against cyclin A, B, D1, E, p21 and p27 were all purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and diluted according to the manufacturer's recommendations.
Immunocytochemistry
Neurosphere cells were grown on laminin-coated glass slides. Cells were fixed with 4% paraformaldehyde for 30 min at 4 1C and permeabilized with PBS containing 0.1% Triton X-100 for 10 min. The cells were then incubated with primary antibodies at 4 1C overnight and then incubated with the appropriate corresponding secondary antibodies conjugated with fluorescent dye for 30 min at room temperature. The primary antibodies were anti-FAK (1:200; Cell Signaling), vinculin (1:100; Millipore, Billerica, MA, USA). The secondary antibodies used for red fluorescence-labeled cells were conjugated with Alexa Fluorescent 488. The secondary antibody used for green fluorescence-labeled cells were conjugated with Alexa Fluorescent 555 or Cy3. For double staining with F-actin, Alexa Fluorescent 647-conjugated phalloidin (1 U; Invitrogen) was used for incubation with the cells. Slides were mounted with Vectashield Antifade solution containing DAPI (Vector Laboratories) and observed by fluorescence microscopy. Immunofluorescent images were taken and analyzed using the Axiovision software (Carl Zeiss Microscope, Thornwood, NY, USA).
Tumor xenografts, immunofluorescence images and immunohistochemistry
For intracranial xenografts, female 4-to 6-week-old SCID immunodeficient mice (National Cancer Institute, Bethesda, MD, USA) received 10 000 viable GBM neurosphere cells in 2 ml of PBS by stereotactic injection into the right caudate/putamen. 63 Cell viability was determined by Trypan blue dye exclusion. Mice were killed 6 --8 weeks after implantation and brains were fixed with 4% paraformaldehyde for 48 h followed by 30% sucrose for 72 --96 h. Frozen brains were embedded with Tissue-Tek OCT Compound (VWR, Radnor, PA, USA) and cut at 20 mm. Brain sections were stained with hematoxylin and eosin according to Lal et al. 63 All animal protocols used in this study were approved by the Johns Hopkins School of Medicine Animal Care and Use Committee.
For immunofluorescent images, brain sections were mounted with Vectashield Antifade solution containing DAPI (Vector Laboratories). Immunofluorescent images were taken by fluorescent microscopy and analyzed using the Axiovision software (Zeiss). To quantify GFP þ or RFP þ cells in brain sections, fluorescent photomicrographs were taken along the periphery of tumors. GFP þ and RFP þ cells in three brain sections from each tumor, including the section with the largest tumor cross-section area, were manually countered.
For Ki-67 staining, brain sections were permeabilized with PBS containing 0.5% Triton X-100 for 5 min. Endogenous peroxidase was blocked with 3% H 2 O 2 . Sections were blocked with 5% normal goat serum and incubated with mouse monoclonal anti-Ki67 (BD Biosciences) at 4 1C overnight. Non-immune mouse IgG was used at the same concentration as negative control. The next day, sections were washed three times with PBS, followed by incubation with biotinylated a goat anti-mouse secondary antibody for 30 min. Signals were detected using the Vectastain ABC kit (Vector Laboratories) and visualized using 3,3 0 -diaminobenzidine. Sections were counterstained with methyl green (0.5%), and dehydrated with 70 and 100% alcohol. Sections were further incubated in xylene and then mounted with Permount. At least 10 sequential bright-field pictures were taken for each tumor under a Â 40 object and Ki-67-positive cells were quantified.
Statistical analysis
Data were analyzed by parametric statistics using one-way analysis of variance. Post-hoc tests included Student's t-test and Tukey's multiple comparison tests as appropriate using Prism (GraphPad, San Diego, CA, USA). All experiments reported here represent at least three independent replications. All data are represented as mean value ± s.e. Significance was set at Po0.05.
